Does Aimovig Reduce Cluster Headaches?
Aimovig (erenumab) is FDA-approved for preventing migraines in adults, targeting the CGRP receptor to block pain signals.[1] It is not approved for cluster headaches, a distinct condition with severe, short-lived attacks often around one eye.[2]
Small studies and case reports suggest potential benefits for some cluster headache patients. A 2020 open-label study of 12 patients with chronic cluster headaches found 58% achieved at least 50% reduction in attack frequency after 3 months on Aimovig 140 mg monthly.[3] Another case series reported partial or complete remission in 7 of 9 refractory episodic cluster headache patients.[4] However, results vary; a 2022 retrospective analysis of 49 patients showed only 35% responders, with many experiencing no change or worsening.[5]
No large randomized controlled trials exist for cluster headaches, so evidence remains anecdotal and preliminary. Guidelines from the American Headache Society do not recommend CGRP blockers like Aimovig as first-line for clusters, favoring oxygen therapy, verapamil, or galcanezumab (another CGRP drug with cluster-specific approval).[6]
How Does Aimovig Compare to Galcanezumab for Clusters?
Galcanezumab (Emgality) is FDA-approved for episodic cluster headache prevention based on two phase 3 trials showing significant weekly attack reductions versus placebo.[7] Aimovig lacks this data. Both block CGRP pathways, but galcanezumab targets the ligand while Aimovig targets the receptor—differences that may explain galcanezumab's stronger evidence in clusters.[8]
| Drug | Cluster Approval | Key Trial Evidence for Clusters |
|------|------------------|-------------------------------|
| Aimovig | No | Small studies: 30-60% response rate in select patients[3][5] |
| Emgality | Yes (episodic only) | Phase 3: 50-70% attack reduction[7] |
What Do Neurologists Say About Off-Label Use?
Experts note Aimovig's cluster data is promising but insufficient for routine use, especially since clusters are rarer and harder to study than migraines.[9] Off-label prescribing occurs in refractory cases, but insurance often denies coverage without approval.[10] Patient forums report mixed results: some describe life-changing relief, others no effect after months.[11]
What Are the Risks and Side Effects?
Common side effects include injection-site reactions (40-50%), constipation (10-20%), and muscle spasms.[1] Rare risks: hypertension, allergic reactions. No unique cluster-related safety signals in studies, but long-term data is limited.[3][5] Clusters' intensity may amplify perceived inefficacy if attacks persist.
Who Might Benefit and What Are Alternatives?
Aimovig shows most promise in chronic or refractory clusters unresponsive to standards like verapamil or steroids.[4] Alternatives:
- Approved: Galcanezumab for episodic; oxygen (inhaled 100%, 15 L/min) for acute attacks (95% effective).[6]
- Others: Prednisone bursts, lithium, topiramate; neuromodulation devices like gammaCore.
Consult a headache specialist—clusters demand rapid, tailored treatment.
Sources:
[1]: FDA Aimovig Label
[2]: International Headache Society Classification
[3]: J Headache Pain, 2020
[4]: Neurology, 2019
[5]: Headache, 2022
[6]: AHS Position Statement
[7]: NEJM, 2019
[8]: Cephalalgia Reviews
[9]: Expert Opin Biol Ther, 2021
[10]: Clusterbusters.org Forum Data
[11]: Reddit r/clusterheads Threads